Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Springerplus
|
May 27, 2014
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
Sara A Hurvitz, Linda D Bosserman, David Chan, et al.
Breast Cancer Research and Treatment
|
October 13, 2015
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Denise A Yardley, Linda D Bosserman, Joyce A O'Shaughnessy, et al.
Clinical Breast Cancer
|
May 13, 2009
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
Adam M Brufsky, Linda D Bosserman, Richard R Caradonna, et al.
Cancer Medicine
|
August 19, 2024
UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
Megan H Wong, Veronica C Jones, Wai Yu, et al.
Journal of Clinical Medicine
|
November 26, 2022
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
Linda D Bosserman, Isa Mambetsariev, Colton Ladbury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer
Catherine H Van Poznak, Sarah Temin, Gary C Yee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update
Gary H Lyman, Sarah Temin, Stephen B Edge, et al.
Journal of Clinical Medicine
|
May 28, 2020
Strategies to Improve Participation of Older Adults in Cancer Research
Jennifer Liu, Eutiquio Gutierrez, Abhay Tiwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2017
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update
Catherine Van Poznak, Mark R Somerfield, William E Barlow, et al.
Breast Cancer Research and Treatment
|
May 17, 2017
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
Denise A Yardley, Edward R Arrowsmith, Brooke R Daniel, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Springerplus
|
May 27, 2014
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer
Sara A Hurvitz, Linda D Bosserman, David Chan, et al.
Breast Cancer Research and Treatment
|
October 13, 2015
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Denise A Yardley, Linda D Bosserman, Joyce A O'Shaughnessy, et al.
Clinical Breast Cancer
|
May 13, 2009
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results
Adam M Brufsky, Linda D Bosserman, Richard R Caradonna, et al.
Cancer Medicine
|
August 19, 2024
UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
Megan H Wong, Veronica C Jones, Wai Yu, et al.
Journal of Clinical Medicine
|
November 26, 2022
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
Linda D Bosserman, Isa Mambetsariev, Colton Ladbury, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2011
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer
Catherine H Van Poznak, Sarah Temin, Gary C Yee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update
Gary H Lyman, Sarah Temin, Stephen B Edge, et al.
Journal of Clinical Medicine
|
May 28, 2020
Strategies to Improve Participation of Older Adults in Cancer Research
Jennifer Liu, Eutiquio Gutierrez, Abhay Tiwari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2017
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update
Catherine Van Poznak, Mark R Somerfield, William E Barlow, et al.
Breast Cancer Research and Treatment
|
May 17, 2017
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
Denise A Yardley, Edward R Arrowsmith, Brooke R Daniel, et al.
Page
of 3